Insider · CIK 0001120478
Dov A Goldstein Md
cfoofficerdirector
Files at BIOA (BioAge Labs, Inc.), GANX (Gain Therapeutics, Inc.), COYA (Coya Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | COYA Coya Therapeutics, Inc. | MOption exercise Common Stock, par value $0.0001 per share | +17,557 | $1.09 | $19k | 27,557 | Aug 19, 2025 |
| Aug 18, 2025 | COYA Coya Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -17,557 | $0.00 | $0 | 0 | Aug 19, 2025 |
| Jun 24, 2025 | GANX Gain Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 25, 2025 |
| Feb 25, 2025 | COYA Coya Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Feb 25, 2025 |
| Feb 18, 2025 | BIOA BioAge Labs, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +170,000 | $0.00 | $0 | 170,000 | Feb 20, 2025 |
| Jan 1, 2025 | COYA Coya Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.